Six-Month Follow-Up
Cross-source consensus on Six-Month Follow-Up from 1 sources and 5 claims.
1 sources · 5 claims
Dosage & preparation
Comparisons
Evidence quality
Highlighted claims
- Six-month follow-up data were available for 2026 patients, or 50.7% of the cohort. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study
- Prescribing declined from discharge to six months for ACEi/ARB/ARNI, beta-blockers, and MRAs. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study
- Among patients discharged on quadruple therapy, about 90% received ACEi/ARB/ARNI and beta-blockers at no more than half of guideline target dose. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study
- SGLT2 inhibitors generally did not require titration and were usually prescribed near guideline target dose. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study
- SGLT2 inhibitor use increased after discharge, suggesting delayed initiation. — Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study